GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neoleukin Therapeutics Inc (NAS:NLTX) » Definitions » E10

Neoleukin Therapeutics (Neoleukin Therapeutics) E10 : $-40.98 (As of Sep. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Neoleukin Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Neoleukin Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2023 was $-1.640. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-40.98 for the trailing ten years ended in Sep. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-05-02), Neoleukin Therapeutics's current stock price is $3.49. Neoleukin Therapeutics's E10 for the quarter that ended in Sep. 2023 was $-40.98. Neoleukin Therapeutics's Shiller PE Ratio of today is .


Neoleukin Therapeutics E10 Historical Data

The historical data trend for Neoleukin Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neoleukin Therapeutics E10 Chart

Neoleukin Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -44.92

Neoleukin Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -45.57 -44.92 -44.38 -43.17 -40.98

Competitive Comparison of Neoleukin Therapeutics's E10

For the Biotechnology subindustry, Neoleukin Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neoleukin Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neoleukin Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Neoleukin Therapeutics's Shiller PE Ratio falls into.



Neoleukin Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Neoleukin Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-1.64/129.8595*129.8595
=-1.640

Current CPI (Sep. 2023) = 129.8595.

Neoleukin Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201312 -13.978 98.326 -18.461
201403 -25.600 99.695 -33.346
201406 -10.200 100.560 -13.172
201409 -11.800 100.428 -15.258
201412 -15.600 99.070 -20.448
201503 -12.000 99.621 -15.642
201506 -8.800 100.684 -11.350
201509 -8.600 100.392 -11.124
201512 -5.400 99.792 -7.027
201603 -7.800 100.470 -10.082
201606 -12.600 101.688 -16.091
201609 -9.200 101.861 -11.729
201612 -9.600 101.863 -12.239
201703 -7.200 102.862 -9.090
201706 -11.800 103.349 -14.827
201709 -10.000 104.136 -12.470
201712 -13.800 104.011 -17.230
201803 -12.400 105.290 -15.294
201806 2.400 106.317 2.931
201809 -12.800 106.507 -15.607
201812 -4.000 105.998 -4.900
201903 -1.800 107.251 -2.179
201906 -0.001 108.070 -0.001
201909 -45.200 108.329 -54.183
201912 -1.200 108.420 -1.437
202003 -3.600 108.902 -4.293
202006 -4.000 108.767 -4.776
202009 -0.800 109.815 -0.946
202012 -4.600 109.897 -5.436
202103 -5.400 111.754 -6.275
202106 -5.400 114.631 -6.117
202109 -5.600 115.734 -6.283
202112 -5.400 117.630 -5.961
202203 -5.600 121.301 -5.995
202206 -5.600 125.017 -5.817
202209 -4.720 125.227 -4.895
202212 -4.840 125.222 -5.019
202303 -5.200 127.348 -5.303
202306 -0.800 128.729 -0.807
202309 -1.640 129.860 -1.640

Add all the adjusted EPS together and divide 10 will get our e10.


Neoleukin Therapeutics  (NAS:NLTX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Neoleukin Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Neoleukin Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Neoleukin Therapeutics (Neoleukin Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
188 East Blaine Street, Suite 450, Seattle, WA, USA, 98102
Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefits over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, which is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.
Executives
Baker Bros. Advisors Lp 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Sean Michael Smith officer: Principal Accounting Officer C/O NEOLEUKIN THERAPEUTICS, INC., 188 E. BLAINE STREET, SUITE 450, SEATTLE WA 98102
Priti Patel officer: Chief Medical Officer C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, #450, SEATTLE WA 98102
Erin Lavelle director C/O ALDER BIOPHARMACEUTICALS, INC., 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Donna Cochener officer: General Counsel, SVP Legal C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, SUITE 450, SEATTLE WA 98102
Rohan Palekar director 201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105
Jonathan G Drachman director, officer: See Remarks 21823 30TH DRIVE SE, BOTHELL WA 98021
Carl Walkey officer: Senior Vice President C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Robert Ho officer: Chief Financial Officer 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Holly Vance officer: General Counsel C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE E., SEATTLE WA 98102
Martin Babler director C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Erin M. Lavelle director 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Redmile Group, Llc 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Jeremy Green 10 percent owner 45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Sarah B. Noonberg director 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080

Neoleukin Therapeutics (Neoleukin Therapeutics) Headlines

From GuruFocus